CSIMarket Company Name, Ticker, Suppliers, else..
 
Rafael Holdings Inc  (NYSE: RFL)
Other Ticker:  
 
 
Price: $1.3700 $-0.06 -4.196%
Day's High: $1.43 Week Perf: -4.2 %
Day's Low: $ 1.37 30 Day Perf: -13.61 %
Volume (M): 27 52 Wk High: $ 2.50
Volume (M$): $ 37 52 Wk Avg: $1.73
Open: $1.39 52 Wk Low: $1.29



 Market Capitalization (Millions $) 33
 Shares Outstanding (Millions) 24
 Employees 18
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Rafael Holdings Inc
Rafael Holdings Inc is a diversified company that owns and operates real estate properties and invests in healthcare assets. It is a subsidiary of IDT Corporation, a multinational holding company. Rafael Holdings primarily focuses on the ownership and management of real estate properties, specializing in commercial and residential spaces. The company also holds a stake in Rafael Pharmaceuticals, a clinical-stage cancer metabolism-based therapeutics company. Overall, Rafael Holdings Inc aims to generate revenue through its real estate properties and investment portfolio.


   Company Address: 520 Broad Street Newark 7102 NJ
   Company Phone Number: 658-1450   Stock Exchange / Ticker: NYSE RFL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CPRX        4.14% 
KALA        4.6% 
VNDA        8.29% 
• View Complete Report
   



Management Changes

Rafael Holdings Realigns Focus on Trappsol Cyclo Amid Leadership Changes and Significant Clinical Trial Milestone

Published Thu, Apr 24 2025 8:15 PM UTC

In an era where the advancement of medical treatments for rare diseases is of paramount importance, Rafael Holdings has reaffirmed its commitment to the development of Trappsol Cyclo, a promising investigational drug for Niemann-Pick Disease Type C1 (NPC1). This milestone announcement comes alongside notable leadership changes as chief executive officer Bill Conkling prepare...
Merger and Acquisition

Cyclo Therapeutics Phase 3 Trial for Trappsol Cyclo in Niemann-Pick Disease Type C1 Fully Enrolled; Interim Results Expected Mid-2025

Published Wed, Mar 26 2025 10:50 AM UTC

Breaking News Cyclo Therapeutics? Phase 3 Clinical Trial for Niemann-Pick Disease Type C1 Fully Enrolled, Interim Analysis Results Anticipated in 2025City, State ? In a groundbreaking development for patients suffering from Niemann-Pick Disease Type C1, Cyclo Therapeutics announced that the Phase 3 clinical trial for their investigational treatment, Trappsol Cyclo, has reach...
Merger and Acquisition

Rafael Holdings: Merging Paths and Financial Foundations Analyzing Q2 Fiscal 2025 and Beyond

Published Thu, Mar 13 2025 9:51 PM UTC

In a notable update for investors and stakeholders, Rafael Holdings, Inc. (NYSE: RFL) has reported its financial results for the second quarter of fiscal 2025, during which the company showcased its diverse portfolio and strategic initiatives. With a current market capitalization of approximately $24 million, Rafael Holdings operates as a diversified holding company with inv...
Merger and Acquisition

A Strategic Union: Rafael Holdings and Cyclo Therapeutics Set to Navigate New Frontiers in Rare Disease Treatment

Published Thu, Aug 22 2024 10:50 AM UTC




In a significant development that promises to reshape the landscape of rare disease treatment, Rafael Holdings (NYSE: RFL) has entered into a definitive merger agreement with Cyclo Therapeutics. This strategic partnership is poised to leverage Rafael s investment capabilities and Cyclo s innovative approaches to pharmaceutical research, particularly with their...
Rafael Holdings Inc

Rafael Holdings Inc Faces Unexpected Setback in First Quarter of 2024 with Revenue Decline and Deficit Per Share

Rafael Holdings Inc, a company operating in the first quarter of 2024 earnings season, experienced a slip into a deficit of $-0.15 per share compared to the previous year's $0.07 per share. This decline in earnings per share was also evident when compared to the prior quarter's $0.04 per share.
The company's revenue for the first quarter decreased by approximately -2.857%, totaling $0.07 million, compared to the $0.07 million revenue from the comparable quarter of the previous year. However, sequentially, the revenue remained unchanged at $0.07 million. It is worth noting that this marks a substantial decrease compared to the earnings of $1.493 million reported in the same quarter a year prior.
One significant signal for the company's performance is the increase in accounts receivable, which indicates a rising demand. The accounts receivable were valued at $2.1 million, higher than the preceding quarter. This suggests that Rafael Holdings Inc has been successful in generating demand for its products or services.






Rafael Holdings Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com